更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 September 10, 2025 01:20 PM GMT China Healthcare | Asia Pacific M Update Initial Thoughts on NYT Article on Chinese Biotech Key Takeaways Article content: The article noted that the draft EO could contain measures/ initiatives on: Beyond the EO, the article also noted considerations to expedite FDA review process. We find the aforementioned measures to be within the range of potential policies envisioned in our recent (report( Exhibit 1 ). Bottom line, we see it remaining comple ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 08 Sep 2025 10:53:38 ET │ 33 pages 1H25 results were fairly in-line with 28% beats and 31% misses among the 445 A and H share companies under Citi coverage. Given PRC 1H25 GDP growth beat but PPI/CPI missed, PRC gov't is pursuing supply-side reforms under the anti-involution framework to boost 2H25E CPI/PPI. From a China equity strategy perspective, we think the key themes of the 15th Five-Year Plan might include economic development, technological innovation, social & people's ...

9月11日，海外利空突袭，AH创新药最终扛住了！ 盘初恐慌情绪集中释放，AH创新药全线重挫，重仓A股创新药的药ETF（562050）一度跌逾4%，100% 聚焦创新药的港股通创新药ETF（520880）跌幅接近8%。 情绪大肆发泄后，行情逐渐缓和，午后明显企稳，药ETF（562050）场内微跌0.7%报收，港股通创新药 ETF（520880）场内最终收跌1.82%，全天振幅达6.67%，成交9.28亿元，环比激增逾88%。 | 序号 | 代码 | 名称 | 现价 | 涨跌幅 | 总市值 | 估算权重 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 9926 | 康方生物 | 127.700 | -4.34% | 1176亿 | 8.54% | | 2 | 1801 | 信达生物 | 97.100 | -2.51% | 1663亿 | 9.43% | | 3 | 1093 | 石药集团 | 10.120 | -7.50% | 1166亿 | 10.14% | | 4 | 6160 | 白济神州 | 193.800 | -6.92% | 2934Z | 10 ...

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Viewpoints - The pharmaceutical industry is experiencing significant differentiation, with innovative drugs, raw materials, and CXO sectors performing well [2][3] - The overall performance of the pharmaceutical industry in 2024 and the first half of 2025 is under pressure, with notable declines in consumer segments, while innovative drugs, raw materials, and CXO show strong growth [2] Summary by Relevant Sections Overall Industry Performance - In 2024, 453 pharmaceutical companies achieved revenue of 2.46 trillion yuan, a year-on-year decline of 0.55%, and a net profit of 148.65 billion yuan, down 8.8%. In the first half of 2025, revenue was 1.22 trillion yuan, a decrease of 2.5%, with net profit at 102 billion yuan, down 2.1% [2][68] Innovative Drugs - In the first half of 2025, innovative drug companies generated revenue of 26.964 billion yuan, a year-on-year increase of 11.78%. Domestic innovative drug companies are transitioning from R&D to commercialization, marking a turning point towards profitability [2][10] Chemical Drugs - Chemical drug companies reported revenue of 198.06 billion yuan in the first half of 2025, a decline of 3.83%, with net profit at 22.14 billion yuan, down 0.11%. Traditional generic to innovative drug companies are performing better [2][10] Medical Devices - Medical device companies achieved revenue of 106.82 billion yuan in the first half of 2025, down 5.32%, with net profit at 17.58 billion yuan, down 18.07%. The sector is under pressure due to inventory and policy impacts, but high-value consumables are showing better performance [2][10] Biological Products - Blood products revenue in 2024 was 24.18 billion yuan, down 1.4%, with net profit of 6.23 billion yuan, up 14.47%. Vaccine companies faced significant declines, with 2024 revenue at 40.77 billion yuan, down 45.3% [2][10] Traditional Chinese Medicine - In the first half of 2025, traditional Chinese medicine companies reported revenue of 174.38 billion yuan, down 4.57%, with net profit of 22.48 billion yuan, up 0.70%. The sector is under pressure from regulatory policies and weak consumer demand [2][10] Raw Materials - Raw material companies achieved revenue of 47.86 billion yuan in the first half of 2025, down 2.90%, but net profit increased by 20.61% to 8.10 billion yuan. High-demand segments like peptides are performing well [2][10] Pharmaceutical Commerce - Pharmaceutical commerce companies reported revenue of 517.86 billion yuan in the first half of 2025, flat year-on-year, with net profit of 12.09 billion yuan, up 7.6% [5] Medical Services - Medical service companies achieved revenue of 36.36 billion yuan in the first half of 2025, down 4.93%, with net profit of 2.35 billion yuan, down 11.17% [5] CXO & Research Services - The CXO and research services sector reported revenue of 50.64 billion yuan in the first half of 2025, up 13.05%, with net profit of 11.91 billion yuan, up 60.6% [5]

Overall Industry Summary - In 2024, 453 pharmaceutical companies achieved revenue of 2.46 trillion yuan, a year-on-year decline of 0.55%, and a net profit of 148.65 billion yuan, down 8.8% [1] - In the first half of 2025, revenue is expected to be 1.22 trillion yuan, a decrease of 2.5%, with a net profit of 102 billion yuan, down 2.1% [1] Innovative Drugs - In the first half of 2025, innovative drug companies achieved revenue of 26.964 billion yuan, a year-on-year increase of 11.78%, indicating strong momentum [1] - Domestic innovative drug companies are transitioning from R&D to commercialization, marking a turning point towards profitability [1] - Outbound licensing has become a second growth curve for biotech companies, providing sustainable funding for R&D through high upfront payments [1] Chemical Drugs - In the first half of 2025, chemical drug companies reported revenue of 198.057 billion yuan, a decline of 3.83%, with a net profit of 22.139 billion yuan, down 0.11% [1] - Traditional generic-to-innovative drug companies performed well, with notable examples including Hengrui Medicine and Haizheng [1] - The chemical drug sector is expected to further differentiate, with innovative companies likely to benefit in the medium to long term [1] Medical Devices - In the first half of 2025, medical device companies achieved revenue of 106.82 billion yuan, down 5.32%, and a net profit of 17.58 billion yuan, down 18.07% [2] - The performance of high-value consumables is driven by factors such as inventory levels and policy impacts, suggesting potential turning points and innovation opportunities [2] Biological Products - Blood products in 2024 generated revenue of 24.18 billion yuan, down 1.4%, with a net profit of 6.23 billion yuan, up 14.47% [2] - Vaccine companies faced significant declines, with 2024 revenue of 40.77 billion yuan, down 45.3%, and a net profit of 3.2 billion yuan, down 72% [2] Traditional Chinese Medicine - In the first half of 2025, traditional Chinese medicine companies reported revenue of 174.376 billion yuan, down 4.57%, with a net profit of 22.479 billion yuan, up 0.70% [3] - The sector is under pressure due to stricter regulations and weak consumer demand, but there are opportunities for leading OTC brands and innovative companies [3] Raw Materials - In the first half of 2025, raw material drug companies achieved revenue of 47.86 billion yuan, down 2.90%, with a net profit of 8.1 billion yuan, up 20.61% [3] - High-performing segments include peptides and vitamin E/A, with companies like Nuotai Bio and New Hecheng showing strong results [3] Pharmaceutical Commerce - In the first half of 2025, pharmaceutical commerce companies reported revenue of 517.86 billion yuan, flat year-on-year, with a net profit of 12.09 billion yuan, up 7.6% [4] - Offline pharmacies achieved revenue of 57.77 billion yuan, up 0.1%, and a net profit of 2.55 billion yuan, up 0.9% [4] Medical Services - In the first half of 2025, medical service companies reported revenue of 36.36 billion yuan, down 4.93%, with a net profit of 2.352 billion yuan, down 11.17% [5] - The performance of eye care companies showed growth, with revenue of 16.102 billion yuan, up 6.75% [5] CXO & Research Services - In the first half of 2025, the CXO and research services sector achieved revenue of 50.64 billion yuan, up 13.05%, with a net profit of 11.91 billion yuan, up 60.6% [6] - The sector continues to show improvement, with leading CXO companies demonstrating strong resilience and growth [6]

Group 1 - The report highlights a significant increase in the amount of share buybacks and repurchases, with a 102% month-on-month growth in planned buyback amounts in August 2025 [4][10][17] - In August 2025, the total amount of completed buybacks in A-shares reached approximately 285.3 billion, marking a 36% increase from July [4][10] - The report indicates that 86% of the funds used for buybacks were from self-owned or raised funds, while 14% came from special loans [4][10] Group 2 - The report notes a substantial increase in the planned repurchase amounts by controlling shareholders, with a rise of 110.1 billion compared to July, totaling 118 billion in new repurchase plans [4][17] - The top three companies with the largest planned repurchase amounts include Changjiang Power, Guizhou Moutai, and Huaxi Biological, with amounts ranging from 30 to 80 billion [17] - In the Hong Kong market, the total buyback amount reached approximately 114.6 billion HKD in August, a 14% increase from July, driven by stock price corrections [20] Group 3 - The report provides a list of companies worth noting for their buyback and repurchase announcements, considering their fundamentals, current valuations, and the proportion of buyback amounts [21][22] - The report includes specific details about companies such as Shengtun Mining and Beijing Keri, highlighting their buyback purposes and amounts [22][23] - The report emphasizes the potential for future expansion of structural monetary policy tools aimed at stabilizing the capital market, which could reshape the A-share ecosystem [7][8]

本文来自格隆汇专栏：阿基米德Biotech 泡沫之塔，一吹即塌。 当创新药出现重度泡沫，非常脆弱之际，命门却被地缘风险一把攫住。9月10日《纽约时报》发文，美国要对中国创新药的对外BD下手了。 本轮创新药盛世经历3个阶段，最初是估值修复，然后是BD和临床事件驱动，当前是流动性推动。然而，今年急剧膨胀至200亿规模的港股通创新药ETF （159570），自9月2日起份额几乎没有增加，恒生生物科技指数（HSHKBIO）9月9日成交额急剧萎缩，9月10日成交额更是跌破200亿，创下8月4日以来 的新低。 这些不详征兆表明，资金暂停流入创新药，危如累卵之际，再来一根地缘风险的稻草。 创新药牛市这么久了，鲜见爆雷事件，仿佛岁月静好，直到康方生物AK112首个全球多中心III期临床受挫，成为转折点，随后坏消息成群结队赶来。 这根稻草可以压垮泡沫，但压不垮中国创新药。 中国创新药的崛起不可逆转，是全球创新资源优化配置的结果，必将涌现一批千亿美元市值企业。CXO已经验证脱钩不可行，创新药产业也将承受住压 力测试。 01 不可动摇的创新源头 美方首次把矛头对准中国创新药BD。 据《纽约时报》，一项草拟的行政命令威胁要切断从中国 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年9月11日斥资1592.66万元人民币回购23.5 万股A股，每股回购价格为67.2-68.41元人民币。 ...

Core Viewpoint - Heng Rui Medicine (600276)(01276) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 235,000 A-shares at a total cost of 15.9266 million RMB [1] - The buyback price per share ranges from 67.2 to 68.41 RMB [1] Financial Implications - The total expenditure for the buyback represents a strategic investment in the company's own shares, potentially enhancing shareholder value [1]